Abstract

Techniques using machine learning for short term blood glucose level prediction in patients with Type 1 Diabetes are investigated. This problem is significant for the development of effective artificial pancreas technology so accurate alerts (e.g. hypoglycemia alarms) and other forecasts can be generated. It is shown that two factors must be considered when selecting the best machine learning technique for blood glucose level regression: (i) the regression model performance metrics being used to select the model, and (ii) the preprocessing techniques required to account for the imbalanced time spent by patients in different portions of the glycemic range. Using standard benchmark data, it is demonstrated that different regression model/preprocessing technique combinations exhibit different accuracies depending on the glycemic subrange under consideration. Therefore technique selection depends on the type of alert required. Specific findings are that a linear Support Vector Regression-based model, trained with normal as well as polynomial features, is best for blood glucose level forecasting in the normal and hyperglycemic ranges while a Multilayer Perceptron trained on oversampled data is ideal for predictions in the hypoglycemic range.

Highlights

  • Type 1 Diabetes (T1D) is an autoimmune disease where the pancreas produces little to no insulin [1]

  • With more recent advancements in technology, systems known as artificial pancreases (APs), improved glycemic control is possible [2]

  • Complete and detailed tables of results with mean and standard deviation performances by algorithm, oversampler and metric are given in S1 Appendix

Read more

Summary

Introduction

Type 1 Diabetes (T1D) is an autoimmune disease where the pancreas produces little to no insulin [1]. Conventional therapy requires patients to inject themselves with insulin multiple times per day. With more recent advancements in technology, systems known as artificial pancreases (APs), improved glycemic control is possible [2]. The standard AP consists of three main components. There is a continuous glucose monitor (CGM) which monitors glycemic levels via a small sensor inserted subcutaneously in either the forearm or the abdomen. The second component is an insulin delivery system, typically a continuous pump, which delivers insulin at either a user-specified or an automatically determined basal rate, subcutaneously. There is a micro-controller linking the two devices together wirelessly, whose main purpose is regulating the insulin pump rate such that time spent in normoglycemia is maximised.

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.